The radiation dose-regulated AND gate genetic circuit, a novel targeted and real-time monitoring strategy for cancer gene therapy

The AND gate functions such that when all inputs are activated the downstream gene will be transcribed and it is off otherwise. To accomplish optimal and targeted gene therapy in solid tumor patients, we have constructed an AND gate genetic circuit and investigated whether it could be activated by low-dose radiation in vitro and in vivo. The enhancement green fluorescent protein (EGFP) expression in different tumor cells transfected with control vector plxsn-EGFP confirmed that 2 Gy of radiation and 1% O2 for 3 h could activate our AND gate. Besides, the obvious different levels of EGFP expression between 2 and 6 Gy of radiation demonstrated that the AND gate could be regulated by radiation doses. Additionally, through EGFP expression and the codistribution of p53 and HIF-1α in xenografts, we illustrated the targeted activation property of the AND gate and real-time monitoring to hypoxic districts in vivo. Moreover, significant growth inhibition and cell cycle arrest in vitro and apoptosis-inducing effects in vitro and in vivo proved that the AND gate induced ideal antitumor effects. In conclusion, the radiation dose-regulated AND gate genetic circuit could not only effectively monitor the therapeutic process in real-time but also induce ideal antitumor efficacy, and can be further exploited for personal therapy in clinical tumor patients.

[1]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[2]  Y. Yamada,et al.  Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[3]  P Vaupel,et al.  Biological consequences of tumor hypoxia. , 2001, Seminars in oncology.

[4]  Y. Naomoto,et al.  Adenovirus-mediated cancer gene therapy and virotherapy (Review). , 2009, International journal of molecular medicine.

[5]  Steve Webb,et al.  Intensity-Modulated Radiation Therapy , 1996, International journal of radiation oncology, biology, physics.

[6]  C. Willett,et al.  Normal-Tissue Tolerance to IOERT, EBRT, or Both: Animal and Clinical Studies , 2011 .

[7]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[8]  Mircea Ivan,et al.  MicroRNA regulation of DNA repair gene expression in hypoxic stress. , 2009, Cancer research.

[9]  Alison M. Dunning,et al.  Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype , 2009, Nature Reviews Cancer.

[10]  G. Tell,et al.  Cross-regulation between Egr-1 and APE/Ref-1 during early response to oxidative stress in the human osteoblastic HOBIT cell line: Evidence for an autoregulatory loop , 2005, Free radical research.

[11]  D. S. St. Clair,et al.  p53 Regulates Oxidative Stress-Mediated Retrograde Signaling: A Novel Mechanism for Chemotherapy-Induced Cardiac Injury , 2011, PloS one.

[12]  S. Webb,et al.  Intensity-Modulated Radiation Therapy – Community Plan Medical Policy , 2019 .

[13]  Zhibin Huang,et al.  Emerging application of stereotactic body radiation therapy for gynecologic malignancies , 2011, Expert review of anticancer therapy.

[14]  T. Molina,et al.  Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker , 2010, Clinical Cancer Research.

[15]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[16]  James B. Mitchell,et al.  Radioprotectors and Mitigators of Radiation-Induced Normal Tissue Injury , 2010, The oncologist.

[17]  J. Ross,et al.  DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions. , 2011, Biochemical pharmacology.

[18]  Rong Li,et al.  Cisplatin‐controlled p53 gene therapy for human non‐small cell lung cancer xenografts in athymic nude mice via the CArG elements , 2005, Cancer science.

[19]  Rong Li,et al.  Enhanced efficacy of radiation‐induced gene therapy in mice bearing lung adenocarcinoma xenografts using hypoxia responsive elements , 2005, Cancer science.

[20]  Songtao Yu,et al.  Noninvasive and real‐time monitoring of the therapeutic response of tumors in vivo with an optimized hTERT promoter , 2012, Cancer.

[21]  T. Pawlik,et al.  Role of cell cycle in mediating sensitivity to radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[22]  J Martin Brown,et al.  Tumor hypoxia in cancer therapy. , 2007, Methods in enzymology.

[23]  P. Lara,et al.  Prediction of normal tissue toxicity as part of the individualized treatment with radiotherapy in oncology patients. , 2012, Surgical oncology.

[24]  Amir Abdollahi,et al.  Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[25]  S. Scott,et al.  Hypoxia- and radiation-activated Cre/loxP ‘molecular switch’ vectors for gene therapy of cancer , 2006, Gene Therapy.

[26]  Igor Jurisica,et al.  Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. , 2011, Cancer research.

[27]  B. Avalosse,et al.  Gene therapy for cancer. , 1995, Current opinion in oncology.

[28]  Christof von Kalle,et al.  Side effects of retroviral gene transfer into hematopoietic stem cells. , 2003, Blood.

[29]  Chi-Ping Day,et al.  Cancer-specific gene therapy. , 2005, Advances in genetics.